HRP20171208T1 - Novi derivati 1-benzil-3-hidroksimetilindazola i njihova uporaba u liječenju bolesti koje se baziraju na ekspresiji cx3cr1 i p40 - Google Patents
Novi derivati 1-benzil-3-hidroksimetilindazola i njihova uporaba u liječenju bolesti koje se baziraju na ekspresiji cx3cr1 i p40 Download PDFInfo
- Publication number
- HRP20171208T1 HRP20171208T1 HRP20171208TT HRP20171208T HRP20171208T1 HR P20171208 T1 HRP20171208 T1 HR P20171208T1 HR P20171208T T HRP20171208T T HR P20171208TT HR P20171208 T HRP20171208 T HR P20171208T HR P20171208 T1 HRP20171208 T1 HR P20171208T1
- Authority
- HR
- Croatia
- Prior art keywords
- group
- carbon atoms
- acid
- hydrogen
- alkyl group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- AIDS & HIV (AREA)
- Child & Adolescent Psychology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08425139 | 2008-03-07 | ||
| EP09717638.2A EP2254869B1 (en) | 2008-03-07 | 2009-03-05 | Neue 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of cx3cr1 und p40 |
| PCT/EP2009/052585 WO2009109613A2 (en) | 2008-03-07 | 2009-03-05 | Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171208T1 true HRP20171208T1 (hr) | 2017-10-06 |
Family
ID=39671487
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160462TT HRP20160462T1 (hr) | 2008-03-07 | 2009-03-05 | Derivati 1-benzil-3-hidroksimetilindazola i njihova uporaba u liječenju bolesti baziranih na ekspresiji mcp-1, cx3cr1 |
| HRP20171208TT HRP20171208T1 (hr) | 2008-03-07 | 2009-03-05 | Novi derivati 1-benzil-3-hidroksimetilindazola i njihova uporaba u liječenju bolesti koje se baziraju na ekspresiji cx3cr1 i p40 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160462TT HRP20160462T1 (hr) | 2008-03-07 | 2009-03-05 | Derivati 1-benzil-3-hidroksimetilindazola i njihova uporaba u liječenju bolesti baziranih na ekspresiji mcp-1, cx3cr1 |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US8835481B2 (enExample) |
| EP (3) | EP3181551A1 (enExample) |
| JP (2) | JP5509101B2 (enExample) |
| KR (2) | KR101599867B1 (enExample) |
| CN (2) | CN101945855B (enExample) |
| AR (2) | AR070811A1 (enExample) |
| AU (2) | AU2009221083B2 (enExample) |
| BR (2) | BRPI0907976A2 (enExample) |
| CA (2) | CA2712403C (enExample) |
| CY (2) | CY1117584T1 (enExample) |
| DK (2) | DK2254869T3 (enExample) |
| EA (2) | EA018241B1 (enExample) |
| ES (2) | ES2637009T3 (enExample) |
| GE (2) | GEP20135983B (enExample) |
| HR (2) | HRP20160462T1 (enExample) |
| HU (1) | HUE027098T2 (enExample) |
| IL (3) | IL206893A0 (enExample) |
| LT (1) | LT2254869T (enExample) |
| MX (2) | MX2010009623A (enExample) |
| PL (2) | PL2254869T3 (enExample) |
| PT (1) | PT2254869T (enExample) |
| SG (1) | SG188177A1 (enExample) |
| SI (2) | SI2254869T1 (enExample) |
| UA (2) | UA103605C2 (enExample) |
| WO (2) | WO2009109618A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101965337B (zh) | 2008-03-07 | 2013-11-06 | 方济各安吉利克化学联合股份有限公司 | 1-苄基-3-羟基甲基吲唑衍生物及其在治疗基于MCP-1、CX3CR1和p40表达的疾病中的用途 |
| PL2254869T3 (pl) * | 2008-03-07 | 2017-10-31 | Acraf | Nowe pochodne 1-benzylo-3-hydroksymetyloindazolu i ich zastosowanie w leczeniu chorób bazujących na ekspresji CX3CR1 i p40 |
| CN101959866B (zh) | 2008-03-07 | 2013-10-02 | 方济各安吉利克化学联合股份有限公司 | 1-苄基-3-羟基甲基吲唑衍生物及其在治疗基于mcp-1和cx3cr1表达的疾病中的用途 |
| CN102471281B (zh) | 2009-08-03 | 2014-10-15 | 方济各安吉利克化学联合股份有限公司 | 1-苄基-3-羟甲基-1h-吲唑及其衍生物以及所需镁中间体的制备方法 |
| UA108742C2 (uk) * | 2009-09-23 | 2015-06-10 | Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1 | |
| US8999292B2 (en) * | 2012-05-01 | 2015-04-07 | Translatum Medicus Inc. | Methods for treating and diagnosing blinding eye diseases |
| CN107050020A (zh) * | 2012-05-01 | 2017-08-18 | 特兰斯拉图姆医学公司 | 用于治疗和诊断致盲性眼病的方法 |
| AU2013261718B2 (en) | 2012-05-18 | 2017-10-19 | Sanofi | Pyrazole derivatives and their use as LPAR5 antagonists |
| EP2850062B1 (en) | 2012-05-18 | 2017-07-19 | Sanofi | Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation |
| US10918588B2 (en) | 2012-11-09 | 2021-02-16 | Colgate-Palmolive Company | Block copolymers for tooth enamel protection |
| JP6625064B2 (ja) * | 2014-05-15 | 2019-12-25 | トランスレイタム メディカス インコーポレイテッド | 眼障害を治療かつ診断するための組成物および方法 |
| BR112017026535B1 (pt) * | 2015-06-12 | 2023-12-19 | Vettore, LLC | Composto e composição farmacêutica |
| EP3310353A4 (en) * | 2015-06-16 | 2019-02-06 | Translatum Medicus, Inc. | COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF EYE DISEASES |
| WO2018111904A1 (en) | 2016-12-12 | 2018-06-21 | Vettore, LLC | Heterocyclic inhibitors of mct4 |
| GB201811169D0 (en) | 2018-07-06 | 2018-08-29 | Kancera Ab | New compounds |
| WO2020026471A1 (ja) * | 2018-07-31 | 2020-02-06 | 株式会社親広産業 | グルコース消費促進剤および解糖系促進剤 |
| JP6612004B1 (ja) * | 2018-07-31 | 2019-11-27 | 株式会社親広産業 | グルコース消費促進剤および解糖系促進剤 |
| EP3990433A4 (en) | 2019-06-25 | 2023-07-26 | Translatum Medicus Inc. | METHODS FOR THE MANUFACTURE OF 2-((1-BENZYL-1H-INDAZOL-3-YL)METHOXY)-2-METHYLPROPANOIC ACID AND ITS DERIVATIVES |
| CN113929627A (zh) * | 2021-10-19 | 2022-01-14 | 吕梁学院 | 一种宾达利的合成方法 |
| WO2024108386A1 (zh) * | 2022-11-22 | 2024-05-30 | 中国科学院深圳先进技术研究院 | 抗mcp1中和抗体在制备治疗神经退行性疾病引起的系统性炎症药物中的应用 |
| EP4662203A1 (en) * | 2023-02-10 | 2025-12-17 | Translatum Medicus Inc. | Bindarit conjugates, compositions and methods for treating ocular diseases or disorders |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US416359A (en) * | 1889-12-03 | Sash-fastener | ||
| US364371A (en) * | 1887-06-07 | peice | ||
| IT1230441B (it) * | 1989-02-07 | 1991-10-23 | Acraf | Eteri della serie dell'indazolo |
| IT1253703B (it) * | 1991-04-22 | 1995-08-23 | Angelini Francesco Ist Ricerca | Uso di acidi metossi alcanoici dell'indazolo per preparare un farmaco attivo nel trattamento di malattie autoimmunitarie |
| IT1293795B1 (it) * | 1997-07-28 | 1999-03-10 | Angelini Ricerche Spa | Farmaco attivo nel ridurre la produzione di proteina mcp-1 |
| JP2003502424A (ja) | 1999-06-17 | 2003-01-21 | シオノギ バイオリサーチ コーポレイション | Ｉｌ−１２産生の阻害物質 |
| EP1199074A1 (en) | 2000-09-15 | 2002-04-24 | Warner-Lambert Company | Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production |
| EP1188438A1 (en) | 2000-09-15 | 2002-03-20 | Warner-Lambert Company | Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production |
| US20040097465A1 (en) | 2001-03-15 | 2004-05-20 | Akira Asari | ll-12 expression controlling agents |
| EP1458687B1 (en) | 2001-11-30 | 2012-01-11 | Synta Pharmaceuticals Corporation | Pyrimidine compounds as interleukin-12 (il-12) inhibitors |
| MXPA06003792A (es) | 2003-10-07 | 2006-06-14 | Astrazeneca Ab | Nuevas 4-amino-tiazolo[4,5-d]-pirimidinas 2-sustituidas, utiles como antagonistas del receptor de quimiocina, especialmente cx3cr1. |
| WO2006046739A1 (ja) * | 2004-10-29 | 2006-05-04 | Eisai R & D Management Co., Ltd. | 炎症性疾患治療剤 |
| WO2006053227A2 (en) | 2004-11-10 | 2006-05-18 | Synta Pharmaceuticals Corp. | Il-12 modulatory compounds |
| JP2008520712A (ja) | 2004-11-19 | 2008-06-19 | シンタ ファーマシューティカルズ コーポレーション | ピリミジン化合物及びその使用 |
| AR053347A1 (es) | 2005-04-06 | 2007-05-02 | Astrazeneca Ab | Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos |
| UA90707C2 (en) | 2005-04-06 | 2010-05-25 | Астразенека Аб | Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives |
| CN101965337B (zh) | 2008-03-07 | 2013-11-06 | 方济各安吉利克化学联合股份有限公司 | 1-苄基-3-羟基甲基吲唑衍生物及其在治疗基于MCP-1、CX3CR1和p40表达的疾病中的用途 |
| PL2254869T3 (pl) | 2008-03-07 | 2017-10-31 | Acraf | Nowe pochodne 1-benzylo-3-hydroksymetyloindazolu i ich zastosowanie w leczeniu chorób bazujących na ekspresji CX3CR1 i p40 |
| CN101959866B (zh) | 2008-03-07 | 2013-10-02 | 方济各安吉利克化学联合股份有限公司 | 1-苄基-3-羟基甲基吲唑衍生物及其在治疗基于mcp-1和cx3cr1表达的疾病中的用途 |
-
2009
- 2009-03-05 PL PL09717638T patent/PL2254869T3/pl unknown
- 2009-03-05 CA CA2712403A patent/CA2712403C/en not_active Expired - Fee Related
- 2009-03-05 KR KR1020107017445A patent/KR101599867B1/ko not_active Expired - Fee Related
- 2009-03-05 HR HRP20160462TT patent/HRP20160462T1/hr unknown
- 2009-03-05 HU HUE09718467A patent/HUE027098T2/en unknown
- 2009-03-05 SI SI200931705T patent/SI2254869T1/sl unknown
- 2009-03-05 SG SG2013013123A patent/SG188177A1/en unknown
- 2009-03-05 MX MX2010009623A patent/MX2010009623A/es active IP Right Grant
- 2009-03-05 AU AU2009221083A patent/AU2009221083B2/en not_active Ceased
- 2009-03-05 DK DK09717638.2T patent/DK2254869T3/en active
- 2009-03-05 JP JP2010549146A patent/JP5509101B2/ja active Active
- 2009-03-05 EP EP17153930.7A patent/EP3181551A1/en not_active Withdrawn
- 2009-03-05 PT PT97176382T patent/PT2254869T/pt unknown
- 2009-03-05 EP EP09717638.2A patent/EP2254869B1/en active Active
- 2009-03-05 EP EP09718467.5A patent/EP2254870B1/en active Active
- 2009-03-05 BR BRPI0907976-9A patent/BRPI0907976A2/pt not_active IP Right Cessation
- 2009-03-05 AU AU2009221089A patent/AU2009221089B2/en not_active Ceased
- 2009-03-05 CA CA2712703A patent/CA2712703C/en not_active Expired - Fee Related
- 2009-03-05 EA EA201071038A patent/EA018241B1/ru not_active IP Right Cessation
- 2009-03-05 BR BRPI0907977-7A patent/BRPI0907977A2/pt not_active IP Right Cessation
- 2009-03-05 SI SI200931404A patent/SI2254870T1/sl unknown
- 2009-03-05 HR HRP20171208TT patent/HRP20171208T1/hr unknown
- 2009-03-05 WO PCT/EP2009/052590 patent/WO2009109618A2/en not_active Ceased
- 2009-03-05 US US12/865,923 patent/US8835481B2/en not_active Expired - Fee Related
- 2009-03-05 MX MX2010009626A patent/MX2010009626A/es active IP Right Grant
- 2009-03-05 US US12/864,767 patent/US7919518B2/en not_active Expired - Fee Related
- 2009-03-05 JP JP2010549143A patent/JP5509099B2/ja active Active
- 2009-03-05 CN CN200980105073.4A patent/CN101945855B/zh not_active Expired - Fee Related
- 2009-03-05 ES ES09717638.2T patent/ES2637009T3/es active Active
- 2009-03-05 PL PL09718467T patent/PL2254870T3/pl unknown
- 2009-03-05 DK DK09718467.5T patent/DK2254870T3/en active
- 2009-03-05 KR KR1020107017806A patent/KR101581828B1/ko not_active Expired - Fee Related
- 2009-03-05 EA EA201071040A patent/EA019711B1/ru not_active IP Right Cessation
- 2009-03-05 ES ES09718467.5T patent/ES2569330T3/es active Active
- 2009-03-05 LT LTEP09717638.2T patent/LT2254869T/lt unknown
- 2009-03-05 WO PCT/EP2009/052585 patent/WO2009109613A2/en not_active Ceased
- 2009-03-05 CN CN200980105556.4A patent/CN101952256B/zh not_active Expired - Fee Related
- 2009-03-05 GE GEAP200911963A patent/GEP20135983B/en unknown
- 2009-03-05 GE GEAP200911965A patent/GEP20135912B/en unknown
- 2009-03-06 AR ARP090100801A patent/AR070811A1/es unknown
- 2009-03-06 AR ARP090100800A patent/AR070810A1/es unknown
- 2009-05-03 UA UAA201008883A patent/UA103605C2/uk unknown
- 2009-05-03 UA UAA201008570A patent/UA105170C2/uk unknown
-
2010
- 2010-07-08 IL IL206893A patent/IL206893A0/en not_active IP Right Cessation
- 2010-07-21 IL IL207131A patent/IL207131A/en not_active IP Right Cessation
-
2011
- 2011-03-07 US US13/041,557 patent/US8283348B2/en not_active Expired - Fee Related
- 2011-10-06 IL IL215579A patent/IL215579A/en not_active IP Right Cessation
-
2016
- 2016-05-13 CY CY20161100406T patent/CY1117584T1/el unknown
-
2017
- 2017-08-09 CY CY20171100858T patent/CY1119252T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171208T1 (hr) | Novi derivati 1-benzil-3-hidroksimetilindazola i njihova uporaba u liječenju bolesti koje se baziraju na ekspresiji cx3cr1 i p40 | |
| HRP20191953T1 (hr) | DERIVATI 1-BENZIL-3-HIDROKSIMETILINDAZOLA I NJIHOVA UPORABA U LIJEČENJU BOLESTI KOJE SE BAZIRAJU NA EKSPRESIJI MCP-1, CXCR1 i p40 | |
| ES2984482T3 (es) | Pirazolo[1,5-a]pirimidinas sustituidas y su uso en el tratamiento de trastornos médicos | |
| JP2024514703A (ja) | ピペラジン構造を有するｐａｒｐ阻害剤、その調製方法およびその医薬的使用 | |
| PE20220143A1 (es) | Agonistas de glp-1r y usos de los mismos | |
| HRP20241656T1 (hr) | Derivat nitrila koji djeluje kao inhibitor dipeptidil peptidaze 1 i njegova upotreba | |
| HRP20160457T1 (hr) | Derivati 1-benzil-3-hidroksimetilindazola i njihova uporaba u liječenju bolesti baziranih na ekspresiji mcp-1 i cx3cr1 | |
| NO20065613L (no) | 3-karbamoyl-2-pyridonderivat. | |
| HRP20090577T8 (en) | Use of crth2 antagonist compounds in therapy | |
| HRP20130900T1 (hr) | Derivat (aza)indola i njegova uporaba u medicinske svrhe | |
| HRP20170695T1 (hr) | Fenil-3-aza-biciklo[3.1.0]heks-3-il-metanoni i njihova uporaba u obliku lijeka | |
| HRP20211762T1 (hr) | Derivati benzoksaborola za liječenje bakterijskih infekcija | |
| HRP20151078T1 (hr) | Pirazoli kao 11-beta-hsd-1 | |
| GT200400174A (es) | Compuestos de bencimidazolona que tienen actividad agonista del receptor 5 ht4 | |
| MY148988A (en) | Terphenyl derivatives for treatment of alzheimer's disease | |
| WO2008148868A8 (en) | Piperidine/piperazine derivatives | |
| CA2758474A1 (en) | Novel p2x7r antagonists and their use | |
| EA200870302A1 (ru) | 1,3-диоксанкарбоновые кислоты | |
| CA2679198A1 (en) | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases | |
| NO20073250L (no) | Non-anilinderivater av isotiazol-3- (2H)-on 1,1-dioksider som lever-X-reseptor modulerende forbindelser. | |
| MX2010001082A (es) | Composicion farmaceutica que contiene compuesto opticamente activo que tiene actividad agonista del receptor de trombopoyetina y compuesto intermedio para el mismo. | |
| ECSP077160A (es) | Nuevos d-homo-estra-1,3,5(10)-trienos sustituidos en la posición 2 como inhibidores de 17 -hidroxiesteroide deshidrogenasa tipo 1 | |
| WO2019241213A1 (en) | 2-naphthimidamides, analogues thereof, and methods of treatment using same | |
| JP2009040767A5 (enExample) | ||
| AR046228A1 (es) | Derivados de indol como activadores ppar, un metodo para su preparacion, composiciones farmaceuticas que los contienen y su empleo en la fabricacion de medicamentos. |